Cryo-Cell International, Inc.

Equities

CCEL

US2288951088

Healthcare Facilities & Services

Market Closed - Nyse 04:10:00 2024-05-02 pm EDT 5-day change 1st Jan Change
8.57 USD +3.38% Intraday chart for Cryo-Cell International, Inc. +9.87% +49.04%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Cryo-Cell International, Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024 CI
Cryo-Cell International to Spin Off Celle Unit, Explore Strategic Alternatives; Shares Jump MT
Cryo-Cell to Explore Strategic Alternatives, Spin-Off Celle CI
Cryo-Cell International, Inc. agreed to Spin-Off Celle Corp. CI
Cryo-Cell International, Inc. Reports Earnings Results for the Full Year Ended November 30, 2023 CI
Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011. CI
Cryo-Cell International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2023 CI
Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011. CI
Cryo-Cell International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2023 CI
Cryo-Cell International, Inc.(NYSEAM:CCEL) added to Russell 3000E Value Index CI
Cryo-Cell International, Inc.(NYSEAM:CCEL) added to Russell Microcap Value Index CI
Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011. CI
Cryo-Cell International, Inc. Reports Earnings Results for the First Quarter Ended February 28, 2023 CI
Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011. CI
Cryo-Cell International, Inc. Reports Earnings Results for the Full Year Ended November 30, 2022 CI
Insider Buy: Cryo Cell International MT
Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011. CI
Cryo-Cell International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2022 CI
Cryo-Cell International, Inc. Primary Exchange Listing will Change to New York Stock Exchange from Nasdaq Capital Market CI
Maxim Starts Cryo-Cell International at Buy With $12 Price Target MT
Cryo-Cell International, Inc.(NYSEAM:CCEL) dropped from NASDAQ Composite Index CI
Cryo-Cell International to Transfer Listing to NYSE American Stock Exchange MT
Cryo-Cell International, Inc. Enters into A Credit Agreement with Susser Bank CI
Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011. CI
Cryo-Cell International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2022 CI
Chart Cryo-Cell International, Inc.
More charts
Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 235,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
8.57 USD
Average target price
9 USD
Spread / Average Target
+5.02%
Consensus
  1. Stock Market
  2. Equities
  3. CCEL Stock
  4. News Cryo-Cell International, Inc.
  5. Cryo-Cell International to Spin Off Celle Unit, Explore Strategic Alternatives; Shares Jump